OTC Markets OTCPK - Delayed Quote USD

Eisai Co., Ltd. (ESALF)

27.75

0.00

(0.00%)

At close: May 23 at 4:00:00 PM EDT

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?

Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.

Investor's Business Daily 24 days ago

BIIB

STOK

ESAIY
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada.

PR Newswire 10 months ago

ESAIY

ESALF
0.00%

Performance Overview

Return	ESALF	Nikkei 225 (^N225)
YTD	+1.06%	-6.85%
1-Year	-32.96%	-4.97%
3-Year	-31.48%	+37.62%